Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Prior treatment of the ITT population (n = 26)

From: A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

   Patients
Surgery 26 100%
 BSO 24 92%
 TAH 22 85%
 Omentectomy 25 96%
Chemotherapy   
 Prior platinum regimen 26 100%
 1 prior line 9 35%
 2 prior lines 2 8%
 3 prior lines 7 27%
 4 prior lines 4 15%
 5 prior lines 4 15%
Best response to most recent chemotherapy   
 CR/NE 6 23%
 PR 5 19%
 SD 3 12%
 PD 11 42%
 Not known 1 4%
Radiotherapy 4 15%
Hormone therapy 3 12%
Immunotherapy 2 8%
  1. BSO, bilateral salpingo-oophorectomy; CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; TAH, total abdominal hysterectomy.